These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9160489)

  • 1. Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event.
    Li QH; Lagakos SW
    Stat Med; 1997 Apr; 16(8):925-40. PubMed ID: 9160489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
    D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumpacker CS; Kahn JO; Richman DD
    Ann Intern Med; 1995 Mar; 122(6):401-8. PubMed ID: 7856987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of late-state HIV infection.
    Millard PS
    J Fam Pract; 1997 Feb; 44(2):132-4. PubMed ID: 9040512
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
    Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
    Baker SG; Fitzmaurice GM; Freedman LS; Kramer BS
    Biostatistics; 2006 Jan; 7(1):29-40. PubMed ID: 15923407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
    Montaner JS; DeMasi R; Hill AM
    AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Delta trial.
    Zaretsky MD
    Lancet; 1997 Feb; 349(9048):358-9. PubMed ID: 9024402
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of didanosine in the management of HIV-1 infection.
    Gazzard BG; Moyle GJ
    Antivir Ther; 1997 Jul; 2(3):135-47. PubMed ID: 11322269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    Clay PG; Rathbun RC; Slater LN
    JAMA; 1999 Jan; 281(2):130; author reply 131. PubMed ID: 9917107
    [No Abstract]   [Full Text] [Related]  

  • 12. Survival analysis for recurrent event data: an application to childhood infectious diseases.
    Kelly PJ; Lim LL
    Stat Med; 2000 Jan; 19(1):13-33. PubMed ID: 10623910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    Haubrich R; Richman D
    JAMA; 1999 Jan; 281(2):130-1. PubMed ID: 9917108
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-HIV therapy (1987-1994): from nothing to confusion].
    Lissen E
    Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285
    [No Abstract]   [Full Text] [Related]  

  • 15. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.
    Lafeuillade A; Poggi C; Tamalet C; Profizi N; Tourres C; Costes O
    J Infect Dis; 1997 May; 175(5):1051-5. PubMed ID: 9129065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A semiparametric Bayesian approach to the random effects model.
    Kleinman KP; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):921-38. PubMed ID: 9750242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residuals for proportional hazards models with interval-censored survival data.
    Farrington CP
    Biometrics; 2000 Jun; 56(2):473-82. PubMed ID: 10877306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viramune triple combo reduces viral load below limit of detection.
    AIDS Patient Care STDS; 1997 Dec; 11(6):456. PubMed ID: 11361870
    [No Abstract]   [Full Text] [Related]  

  • 20. Incorporating prior beliefs about selection bias into the analysis of randomized trials with missing outcomes.
    Scharfstein DO; Daniels MJ; Robins JM
    Biostatistics; 2003 Oct; 4(4):495-512. PubMed ID: 14557107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.